BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• BioCryst Pharmaceuticals has received a consensus rating of "Moderate Buy" from analysts, with one hold and nine buy recommendations.
• The company reported an earnings per share (EPS) of $0.15 for the quarter, significantly surpassing estimates of $0.03, along with a revenue growth of 49.5% year-over-year.
• Analysts have varying target prices for BCRX stock, with estimates ranging from $13.00 to $30.00, reflecting strong investor interest and confidence in the company’s future performance.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $16.70.

BCRX has been the topic of several research reports. JPMorgan Chase & Co. lifted their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Royal Bank Of Canada reiterated an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wedbush upped their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Arrowstreet Capital Limited Partnership lifted its stake in shares of BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after purchasing an additional 4,084,403 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of BioCryst Pharmaceuticals by 25,631.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after purchasing an additional 3,606,566 shares during the last quarter. Millennium Management LLC lifted its stake in shares of BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. Eversept Partners LP lifted its stake in shares of BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after purchasing an additional 1,444,907 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in shares of BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock worth $21,266,000 after acquiring an additional 1,432,824 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.12 during trading on Monday, reaching $8.42. 789,278 shares of the stock traded hands, compared to its average volume of 3,847,746. The company has a 50-day moving average of $9.16 and a 200-day moving average of $8.77. The stock has a market capitalization of $1.77 billion, a P/E ratio of -46.24, a price-to-earnings-growth ratio of 1.90 and a beta of 1.10. BioCryst Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. The business's quarterly revenue was up 49.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) earnings per share. Analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.